

World Journal of *Gastroenterology*

World J Gastroenterol 2017 October 21; 23(39): 7059-7200



**REVIEW**

- 7059** Less common etiologies of exocrine pancreatic insufficiency

Singh VK, Haupt ME, Geller DE, Hall JA, Quintana Diez PM

MINIREVIEWS

- 7077** Radiofrequency ablation for hepatic hemangiomas: A consensus from a Chinese panel of experts

Gao J, Fan RF, Yang JY, Cui Y, Ji JS, Ma KS, Li XL, Zhang L, Xu CL, Kong XL, Ke S, Ding XM, Wang SH, Yang MM, Song JJ, Zhai B, Nin CM, Guo SG, Xin ZH, Lu J, Dong YH, Zhu HQ, Sun WB

ORIGINAL ARTICLE**Basic Study**

- 7087** Detection of *KRAS* G12D in colorectal cancer stool by droplet digital PCR

Olmedillas-López S, Lévano-Linares DC, Aúz Alexandre CL, Vega-Clemente L, León Sánchez E, Villagrasa A, Ruiz-Tovar J, García-Arranz M, García-Olmo D

- 7098** Optimal timing for the oral administration of Da-Cheng-Qi decoction based on the pharmacokinetic and pharmacodynamic targeting of the pancreas in rats with acute pancreatitis

Zhang YM, Zhu L, Zhao XL, Chen H, Kang HX, Zhao JL, Wan MH, Li J, Zhu L, Tang WF

Retrospective Study

- 7110** Short- and long-term results of endoscopic ultrasound-guided transmural drainage for pancreatic pseudocysts and walled-off necrosis

Watanabe Y, Mikata R, Yasui S, Ohyama H, Sugiyama H, Sakai Y, Tsuyuguchi T, Kato N

- 7119** Laparoscopic finding of a hepatic subcapsular spider-like telangiectasis sign in biliary atresia

Zhou Y, Jiang M, Tang ST, Yang L, Zhang X, Yang DH, Xiong M, Li S, Cao GQ, Wang Y

- 7129** Digestive tract reconstruction using isoperistaltic jejunum-later-cut overlap method after totally laparoscopic total gastrectomy for gastric cancer: Short-term outcomes and impact on quality of life

Huang ZN, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Lin JL

Observational Study

- 7139** Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

Luchetti MM, Benfaremo D, Ciccio F, Bolognini L, Ciferri M, Farinelli A, Rossini M, Mosca P, Triolo G, Gabrielli A

- 7150** Presence of columnar-lined esophagus is negatively associated with the presence of esophageal varices in Japanese alcoholic men
Yokoyama A, Hirata K, Nakamura R, Omori T, Mizukami T, Aida J, Maruyama K, Yokoyama T
- 7160** Characteristics and outcomes of cholangiocarcinoma by region in Thailand: A nationwide study
Chaiteerakij R, Pan-ngum W, Poovorawan K, Soonthornworasiri N, Treeprasertsuk S, Phaosawasdi K
- 7168** Expression of annexin A5 in serum and tumor tissue of patients with colon cancer and its clinical significance
Sun CB, Zhao AY, Ji S, Han XQ, Sun ZC, Wang MC, Zheng FC

CASE REPORT

- 7174** Faecal microbiota transplantation in patients with *Clostridium difficile* and significant comorbidities as well as in patients with new indications: A case series
Lahtinen P, Mattila E, Anttila VJ, Tillonen J, Teittinen M, Nevalainen P, Salminen S, Satokari R, Arkkila P
- 7185** Oval mucosal opening bloc biopsy after incision and widening by ring thread traction for submucosal tumor
Mori H, Kobara H, Guan Y, Goda Y, Kobayashi N, Nishiyama N, Masaki T
- 7191** Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis
Shin S, Moh IH, Woo YS, Jung SW, Kim JB, Park JW, Suk KT, Kim HS, Hong M, Park SH, Lee MS

LETTERS TO THE EDITOR

- 7198** Duplicate publication bias weakens the validity of meta-analysis of immunosuppression after transplantation
Fairfield CJ, Harrison EM, Wigmore SJ

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, İlhami Yüksel, MD, Associate Professor, Gastroenterology, Yildirim Beyazıt University School of Medicine, Ankara 06100, Turkey

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Yan Huang
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Ze-Mao Gong
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
October 21, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Radiofrequency ablation for hepatic hemangiomas: A consensus from a Chinese panel of experts

Jun Gao, Rui-Fang Fan, Jia-Yin Yang, Yan Cui, Jian-Song Ji, Kuan-Sheng Ma, Xiao-Long Li, Long Zhang, Chong-Liang Xu, Xin-Liang Kong, Shan Ke, Xue-Mei Ding, Shao-Hong Wang, Meng-Meng Yang, Jin-Jin Song, Bo Zhai, Chun-Ming Nin, Shi-Gang Guo, Zong-Hai Xin, Jun Lu, Yong-Hong Dong, Hua-Qiang Zhu, Wen-Bing Sun

Jun Gao, Shan Ke, Xue-Mei Ding, Shao-Hong Wang, Meng-Meng Yang, Wen-Bing Sun, Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100043, China

Rui-Fang Fan, Department of Hepatobiliary Surgery, Lanzhou General Hospital of Lanzhou Military Region, Lanzhou 730050, Gansu Province, China

Jia-Yin Yang, Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Yan Cui, Department of General Surgery, the 306th Hospital of Chinese People's Liberation Army, Beijing 100012, China

Jian-Song Ji, Jin-Jin Song, Department of Radiology, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical College, Wenzhou 32300, Zhejiang Province, China

Kuan-Sheng Ma, Institute of Hepatobiliary Surgery, Southwest Hospital, The Third Military Medical University, Chongqing 400038, China

Xiao-Long Li, Long Zhang, Department of General Surgery, Affiliated Hospital of Chifeng University, Chifeng 024000, Inner Mongolia Autonomous Region, China

Chong-Liang Xu, Xin-Liang Kong, Department of Hepatobiliary Surgery, Rizhao People's Hospital, Rizhao 276801, Shandong Province, China

Bo Zhai, Department of Tumor Intervention, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

Chun-Ming Nin, Shi-Gang Guo, Department of General Surgery, Chaoyang Central Hospital, Chaoyang 122000, Liaoning Province, China

Zong-Hai Xin, Department of General Surgery, Zhanhua People's

Hospital, Zhanhua 256800, Shandong Province, China

Yong-Hong Dong, Department of General Surgery, Shanxi Provincial People's Hospital, Taiyuan 032200, Shanxi Province, China

Jun Lu, Hua-Qiang Zhu, Department of General Surgery, Shandong Provincial People's Hospital, Jinan 250021, Shandong Province, China

ORCID number: Jun Gao (0000-0003-3837-3956); Rui-Fang Fan (0000-0001-9418-4258); Jia-Yin Yang (0000-0001-9134-1959); Yan Cui (0000-0002-6833-5611); Jian-Song Ji (0000-0003-1314-396x); Kuan-Sheng Ma (0000-0002-5380-389x); Xiao-Long Li (0000-0002-4953-4703); Long Zhang (0000-0003-3499-1319); Chong-Liang Xu (0000-0001-6379-7086); Xin-Liang Kong (0000-0001-8587-3166); Shan Ke (0000-0002-0907-7632); Xue-Mei Ding (0000-0002-9102-3691); Shao-Hong Wang (0000-0001-5421-2971); Meng-Meng Yang (0000-0001-7556-2890); Jin-Jin Song (0000-0002-2026-8755); Bo Zhai (0000-0003-4337-7126); Chun-Ming Nin (0000-0002-4717-7845); Shi-Gang Guo (0000-0002-9871-6220); Zong-Hai Xin (0000-0002-2694-7126); Jun Lu (0000-0002-2662-5397); Yong-Hong Dong (0000-0001-5100-5061); Hua-Qiang Zhu (0000-0002-6512-9599); Wen-Bing Sun (0000-0003-0919-2494).

Author contributions: Gao J and Sun WB performed the research and wrote the paper; Fan RF, Yang JY, Cui Y, Ji JS, Ma KS, Li XL, Zhang L, Xu CL, Kong XL, Ke S, Ding XM, Wang SH, Yang MM, Song JJ, Zhai B, Nin CM, Guo SG, Xin ZH, Lu J, Dong YH and Zhu HQ contributed to the critical revision of the manuscript for important intellectual content.

Supported by National Natural Science Foundation of China, No. 81502650, No. 81572957, No. 81573657, No. 30872490 and No. 81172320; the Program for High-level Technical Talents in Beijing Health System, No. 2015-03-025 and No. 2009-03-11; and Dr. Wu Jie-Ping Medical Foundation, No. 320675007131 and No. 32067501207.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Wen-Bing Sun, MD, Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital Affiliated to Capital Medical University, No. 5, Jingyuan Street, Beijing 100043, China. sunwenbing@bjcyh.com
Telephone: +86-10-51718372
Fax: +86-10-51718017

Received: July 30, 2017

Peer-review started: July 30, 2017

First decision: August 29, 2017

Revised: September 13, 2017

Accepted: September 19, 2017

Article in press: September 19, 2017

Published online: October 21, 2017

Abstract

Recent studies have shown that radiofrequency (RF) ablation therapy is a safe, feasible, and effective procedure for hepatic hemangiomas, even huge hepatic hemangiomas. RF ablation has the following advantages in the treatment of hepatic hemangiomas: minimal invasiveness, definite efficacy, high safety, fast recovery, relatively simple operation, and wide applicability. It is necessary to formulate a widely accepted consensus among the experts in China who have extensive expertise and experience in the treatment of hepatic hemangiomas using RF ablation, which is important to standardize the application of RF ablation for the management of hepatic hemangiomas, regarding the selection of patients with suitable indications to receive RF ablation treatment, the technical details of the techniques, therapeutic effect evaluations, management of complications, *etc.* A final consensus by a Chinese panel of experts who have the expertise of using RF ablation to treat hepatic hemangiomas was reached by means of literature review, comprehensive discussion, and draft approval.

Key words: Hepatic hemangiomas; Radiofrequency ablation; Consensus

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Recent studies have shown that radiofrequency (RF) ablation therapy is a safe, feasible, and effective procedure for hepatic hemangiomas. It is necessary to formulate a widely accepted consensus among the experts in China who have extensive expertise and experience in the treatment of hepatic hemangiomas using RF ablation, which is important to standardize the application of RF ablation for the management of hepatic hemangiomas.

Gao J, Fan RF, Yang JY, Cui Y, Ji JS, Ma KS, Li XL, Zhang L, Xu CL, Kong XL, Ke S, Ding XM, Wang SH, Yang MM, Song JJ, Zhai B, Nin CM, Guo SG, Xin ZH, Lu J, Dong YH, Zhu HQ, Sun WB. Radiofrequency ablation for hepatic hemangiomas: A consensus from a Chinese panel of experts. *World J Gastroenterol* 2017; 23(39): 7077-7086 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i39/7077.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i39.7077>

INTRODUCTION

Hepatic hemangioma is the most common benign tumor of the human liver, with an incidence of 0.4% to 20% in the general population and a prevalence of 0.4% to 7.3% incidentally found in autopsy^[1-5]. Most incidentally identified and asymptomatic hepatic hemangiomas do not need medical interventions. However, therapies are warranted for giant hepatic hemangiomas (≥ 5 cm) that cause significant symptoms or the peripherally located hemangiomas posing the risk of life-threatening spontaneous rupture and hemorrhage^[6-10].

Hepatic hemangiomas have been treated with a wide spectrum of therapies. Traditionally, surgical resection and surgical enucleation are the mostly used treatments of choice^[6-10]. Minimally invasive therapies for hepatic hemangioma include transcatheter arterial embolization (TAE)^[11-14], radiation therapy^[15,16], and radiofrequency (RF) ablation^[17-37]. Orthotopic liver transplantation has been performed as the treatment choice in rare circumstances^[38]. In recent years, RF ablation has been increasingly used for managing hepatic hemangiomas due to its unique advantages compared with other therapies, such as minimal invasiveness, low cost, low incidence of complications, short duration of hospital stay, and increased patient compliance^[17-37]. So far, 501 patients with hemangiomas treated by RF ablation have been reported in the literature^[17-37]. A widely accepted consensus or guideline, embracing the selection of patients with suitable indications to receive RF ablation treatment, the application of the techniques, therapeutic effect evaluations, and management of complications, is needed to standardize the management of hepatic hemangiomas using RF ablation.

CONSENSUS DEVELOPMENT

The literature search was performed with an inclusion of published articles during the period from 2003 to 2017. The searched database is Medline. Medical subject headings and free-text words were used for searches, including radiofrequency ablation and hepatic hemangioma. Twenty-one original research papers pertinent to RF ablation treatment for hepatic hemangiomas were included. Of the 21 included papers (501 patients), 13 (465 patients) came from China, including ten in English and three in Chinese^[17-37]; two came from South Korea, in which 25 patients with hepatic hemangiomas underwent ultrasound-guided percutaneous RF ablation^[21,25]; and Western experience contributed six case reports including 11 patients on the RF ablation for hepatic hemangiomas^[18,23,24,26,30,36]. Studies were reviewed and selected for further screening analyses and for subsequent consensus studies.

Base on a comprehensive appraisal of the published original research articles related to RF ablation for hepatic hemangiomas, a Chinese panel of experts was contacted and convened by electronic mails and/or phone. The recruitment of the experts was determined based on the following comprehensive criteria: the number of reported cases using RF ablation for hepatic hemangiomas and the impact of the published articles. All the experts work in well-known, high-volume centers, and their clinical experiences are well documented in scientific papers. They reviewed both the literature and their institutional experience. The draft was completed by the corresponding author and his team and then was circulated to all participants for comments. The revised version was redistributed to the experts for approval or further comments. After more than nine months of electronic mail or, on occasion, face-to-face discussions, the final version of consensus was formulated.

OVERVIEW OF HEPATIC HEMANGIOMAS

Pathology and clinical features

Hepatic hemangioma is usually a solitary tumor mass, although multiple lesions may be present in both hepatic lobes in up to 40% of the patients. Hepatic hemangiomas include cavernous hemangioma, sclerosing hemangioma, hemangioendothelioma, and capillary hemangioma. It consists of blood-filled cavities fed by the hepatic arterial circulation, with walls lined by a single layer of endothelial cells, and manifests as a veritable chaotic entanglement of distorted blood vessels confined to a region as small as a few milliliters and as large as 10 cm, 20 cm, and even 40 cm^[1-3].

According to the diameter of hepatic hemangioma, it could be divided into three categories: small (<5 cm), giant (5-9.9 cm), and huge (≥ 10 cm). Giant hemangiomas are also defined by a diameter larger

than 4 cm in the literature^[1-5].

Diagnosis

In most situations, hepatic hemangiomas (especially when smaller than 4 cm) do not show any signs and/or symptoms, most likely being discovered incidentally during imaging investigations for other unrelated conditions. However, a few patients may present a wide variety of non-specific clinical symptoms such as pain in the right upper abdomen, decreased appetite, premature satiation sensation, nausea, vomiting, and abdominal discomfort such as sense of fullness and postprandial bloating (early or late). Spontaneous or traumatic rupture is the most severe complication. This has a catastrophic outcome if not promptly managed, and is the reason why correct diagnosis and management are extremely important^[1-3].

Hepatic hemangiomas can be specifically diagnosed by ultrasonography (US) or contrast-enhanced US, contrast-enhanced computed tomography (CT), and magnetic resonance imaging (MRI) because of their typical imaging characteristics^[4]. On US images, hepatic hemangiomas present as a homogeneous, round or oval lesion with well-defined hyperechogenicity, and likelihood of posterior acoustic enhancement. Other imaging techniques, such as contrast-enhanced CT or MRI, are recommended for confirmation in case of inconclusive ultrasonographic results, or if a giant hemangioma requires treatment^[4,5]. The typical hemangioma appears on CT or MRI scans as a hypointense, well-defined lesion, which after contrast injection shows peripheral nodular enhancement with progressive homogeneous centripetal filling.

TRADITIONAL TREATMENT OF HEPATIC HEMANGIOMAS

Surgical procedure used to be the first choice of treatment for hepatic hemangiomas, including hemangioma enucleation, lobectomy (segmentectomy) or partial hepatectomy, and tumor suture or ligation^[6-10]. Liver transplantation is used for rare cases which need medical intervention but the tumor is too large to undergo surgical resection, ruptures, or has hemorrhage combined with Kasabach-Merritt syndrome^[38]. Surgical resection is rather invasive and associated with relatively high risks of perioperative morbidity (27%), mortality (3%) and long hospitalization^[6-10].

Radiation therapy can destroy the endothelial cells and smooth muscle cells of hepatic hemangiomas, consequently leading to thrombosis, necrosis, and fibrosis inside the tumors, which provides partial reduction in hemangioma size and relief of symptoms. Currently, radiation therapy is used rarely in hepatic hemangioma because it is not considered as a

curative therapy. Moreover, it may have the risks of radiation hepatitis, veno-occlusive disease, and hepatic neoplasia^[15,16].

TAE has been undertaken as an effective alternative treatment for managing hepatic hemangioma. Before TAE, hepatic arterial angiography is carried out to assess the blood supply to the tumor, tumor size, tumor number, tumor position, and intrahepatic vascular variants. The superselective catheterization of the hepatic arteries leading to the tumor body is followed by embolizing the tumor vessels using an embolization agent mixed with pingyangmycin or bleomycin. With the destruction of endothelial cells lining the blood sinus, thrombosis is formed to block the blood supply to the body of hemangioma. However, TAE is not considered as curative because recurrence is common due to vascular recanalization^[34]. Moreover, the treatment may have disastrous complications, such as systemic embolization, biliary damage, and hepatic rupture as the size of tumors increases^[11,12]. Several reports have advocated TAE as a temporizing and auxiliary preoperative procedure for huge hepatic hemangioma or spontaneously ruptured hemangiomas to decrease the risk of surgery^[11-14,34].

HISTORY OF RF ABLATION FOR HEPATIC HEMANGIOMAS

RF ablation is performed by using RF-induced thermal energy to damage the endothelial lining vascular structures as a result of promoting thrombosis^[18], to induce necrotic coagulation^[19], as well as to destruct erythrocytes and cause vascular smooth muscle cell disappearance and fibrosis in the ablated zone^[19].

In 2003, Cui *et al.*^[17] reported the first cohort of 12 patients who received the percutaneous RF ablation treatment for 15 hepatic hemangiomas (2.5-9.5 cm) under US guidance. In 2004, Zagoria *et al.*^[18] reported the successful treatment of a symptomatic hepatic hemangioma (5.0 cm) using percutaneous RF ablation under CT guidance. A few more studies show that percutaneous RF ablation therapy is a safe, minimally invasive, and effective locoregional treatment for selected patients with hepatic hemangiomas^[21,23]. In 2006, Fan *et al.*^[20] reported the use of laparoscopic RF ablation therapy for treating 21 patients with 50 hepatic hemangiomas (5.5 cm \pm 2.0 cm) located on the surface of the liver or adjacent to the gallbladder. The results showed that laparoscopic RF ablation therapy is a safe, feasible, and effective treatment option for patients with extrorse hemangiomas. In 2016, a prospective study demonstrated the benefits and disadvantages of laparoscopic RF ablation as compared with surgical resection for managing hepatic hemangioma^[35]. Sixty-six patients with symptomatic-

enlarging hepatic hemangiomas (4 cm \leq diameter < 10 cm) either underwent laparoscopic RF ablation ($n = 32$) or open resection ($n = 34$). Laparoscopic RF ablation was associated with significantly shorter operative time (138 min vs 201 min, $P < 0.001$) and less blood loss than open resection. Patients after laparoscopic RF ablation experienced significantly less pain and required less analgesia use, significantly shorter length of hospital stay, and lower hospital cost. The study showed that laparoscopic RF ablation, as a minimal invasive treatment option, is as safe and effective a procedure as open resection for patients with symptomatic-enlarging hepatic hemangiomas smaller than 10 cm.

During the initial period of RF ablation for hepatic hemangiomas, authors always selected and treated hepatic hemangiomas < 10 cm using RF ablation because of the lack of experience. Sporadic cases with huge hepatic hemangiomas were treated by RF ablation. Whether RF ablation should be accepted for treating huge hemangiomas is still in debate because of the requirement of long ablation time. Lengthy ablation time is prone to cause hemolysis, which can lead to the complications of hemoglobinuria, hemolytic jaundice, anemia, or even acute kidney injury (AKI)^[25-36]. The incidence of complications post RF ablation is proportionally associated with the size of hemangiomas and the ablation time^[28-36]. Park *et al.*^[25] described the 100% ablation of 10 hepatic hemangiomas larger than 5 cm but less than 10 cm and an ablation in 60% (3/5) of hepatic hemangiomas ≥ 10 cm. Hence, they drew a conclusion that the best indication for RF ablation was giant hepatic hemangiomas, but huge hepatic hemangiomas were the comparative contraindication. Gao *et al.*^[28] reported the same technical difficulties when they treated 17 huge hemangiomas ≥ 10 cm in 16 patients with RF ablation using cluster electrodes. In their study a high rate of complete ablation (82.4%, 14/17) was achieved, but ablation-related complications were seen in all the 16 patients with hemangiomas ≥ 10 cm, including significant systemic inflammatory responses and acute respiratory distress syndrome (ARDS, grade IV)^[39]. Gao *et al.*^[31] adopted two approaches to treat 21 large hemangiomas in 21 patients with the expectation of lessening the incidence of complications and achieving a higher success rate: (1) using cool-tip cluster electrodes; and (2) closely monitoring the patient's temperature and hemoglobinuria to warrant a termination of the procedure if the temperature exceeds 39 °C or signs of hemoglobinuria appeared. Complete ablation was achieved in 90.5% (19/21) of cases and ablation-related complications reduced to 47.6% (10/21). According to the Dindo-Clavien classification for complications^[39], all the complications were grade I (including hemoglobinuria in ten cases,

Table 1 Indications and contraindications of radiofrequency ablation for hepatic hemangiomas

Indications
The maximum diameter of hemangiomas > 5 cm
Tumor gaining an enlargement of more than 1 cm within 2 yr
Persistent hemangioma-related abdominal pain or discomfort
Consent to receive the RF ablation
Contraindications
Severe bleeding tendency, platelets < 50 × 10 ⁹ /L, international normalized ratio > 1.5, severe platelet function disorders (prothrombin time > 18 s and prothrombin activity < 40%)
Malignant tumors
Kasabach-Merritt syndrome
Infection, especially biliary system inflammation
Low immune function
Severe primary organ failure such as the liver, kidney, heart, lung and/or brain

fever in four cases, hemolytic jaundice in three cases, anemia in one case, and elevated serum transaminase in four cases). Eighteen patients required one session and three patients with hemangiomas ≥ 14.0 cm required two sessions of RF ablation. This study by Gao *et al.*^[31] showed that RF ablation for huge hepatic hemangiomas is minimally invasive, safe, and effective. Other studies reported the similar results^[27,30].

INDICATIONS AND CONTRAINDICATIONS FOR RF ABLATION FOR HEPATIC HEMANGIOMAS

Indications

Indications include: the maximum diameter of hemangiomas > 5 cm; on regular imaging follow-up, tumor gaining an enlargement of more than 1 cm within 2 years; persistent hemangioma-related abdominal pain or discomfort with the definite exclusion of other gastrointestinal diseases which cause the epigastric pain *via* gastroscopy examinations; patients' decline to receive surgical treatment but with the consent to receive the RF ablation (Table 1)^[25-34].

Contraindications

Contraindications include: patients with severe bleeding tendency, platelets < 50 × 10⁹/L, severe platelet function disorders (prothrombin time > 18 s and prothrombin activity < 40%), international normalized ratio > 1.5, malignant tumors, Kasabach-Merritt syndrome, infection, especially biliary system inflammation, low immune function, and severe primary organ failure such as the liver, kidney, heart, lung and/or brain^[28-34]. Anticoagulation and/or antiplatelet drugs should be discontinued at least 5-7 d prior to ablation (Table 1).

ANESTHESIA PROTOCOLS

For percutaneous procedures, general anesthesia is recommended to prevent pain and discomfort during RF procedure. Controlled ventilation would reduce ablation attempts and increase the success rate while RF ablation is performed for patients under general anesthesia^[31-35].

PROCEDURES OF RF ABLATION

RF ablation for hepatic hemangiomas can be performed *via* a percutaneous, laparotomy or laparoscopic approach. The diversity of approaches helps extend the scope of treatment indications^[25-34].

Hepatic hemangiomas deeply located in liver parenchyma are suited to be treated by percutaneous CT-guided RF ablation. After induction of general anesthesia, patients are placed in a supine position. Grounding is achieved by attaching two pads to the patient's thighs. The skin entry point of the RF electrodes is determined by the guidance of CT imaging. Under the monitoring and guidance of CT, the RF electrodes are percutaneously inserted through the liver to target the tumor. After CT images confirm the acting tip of the RF electrode is located in the tumor center, RF procedure is performed^[28].

Subcapsular hepatic hemangioma is suitable to be treated *via* a laparoscopic approach using US guidance^[20,33,35]. Under general anesthesia, patients were placed in a supine position. After a pneumoperitoneum (CO₂ at 12 mmHg) is established, a thorough intraperitoneal exploration with a 30° laparoscope through a 10-mm umbilical port is performed. Another 10 mm subxiphoid port is created at the midline of abdomen and an additional 10 mm right or left lateral subcostal port is placed if needed, depending on the location of the hepatic hemangiomas. Under US guidance, the RF electrodes are introduced into the peritoneal cavity through the subcostal abdominal wall under the direct laparoscopic view and deployed into the tumor. The RF procedure is monitored by intraoperative US, which can increase the ability to guide the RF electrode placement and evaluate the efficacy of ablation. After ablation, the ablated lesion became hyperechoic because of outgassing from heated tissues. Laparoscopic biopsy of liver lesions before the ablation is not needed with the consideration of avoiding unnecessary bleeding. For the patients with gallbladder stones or simple hepatic cysts, laparoscopic cholecystectomy (LC) or deroofing of the hepatic cysts may be performed during ablation. LC had to be performed beforehand if the lesions are encroaching on the gallbladder fossa.

Laparotomy is more invasive than percutaneous and laparoscopic approaches. With the increasing

experiences in RF ablation and the improvement of laparoscopic techniques, laparotomy is only used for an alternative approach. In case of unexpected incidence of uncontrollable bleeding during the procedure *via* percutaneous and laparoscopic approaches, laparotomy needs to be performed for controlling the bleeding efficiently and preventing the occurrence of severe complications.

TECHNICAL DETAILS TO BE NOTED

Common strategies of ablation for hepatic hemangiomas

A transhepatic route for RF electrode placement to target the tumor is recommended to prevent bleeding from the electrode-poking site of hemangiomas. RF ablation is initiated at the treatment point close to the margin of the tumor to minimize the risk of bleeding and the heat sink effect. The heat sink effect refers to cooling by adjacent visible (>1 mm diameter) blood vessels when ablated tissues are heated. Overlapped ablation zones are warranted by repositioning the RF electrodes in the tumor mass repeatedly under the guidance and monitoring of CT or US imaging, ensuring a complete ablation of the tumors. An intratumoral ablation is necessary to minimize injuries to normal liver parenchyma and the needle tract ablation can prevent the incidence of needle puncture-induced bleeding^[31].

In the laparoscopic approach, the Pringle maneuver can be used to decrease the heat sink effect^[28]. Furthermore, the laparoscopic approach also offers a direct vision of the entire RF procedure, which is helpful to identify and manage bleeding from the puncture site or tumor rupture^[31-33].

Based on our experience on treating 76 huge hepatic hemangiomas^[31-33], we prefer to use internally cooled cluster electrodes to treat the tumors by taking their advantage of achieving an efficient and much concentrated thermal energy in the tumor tissue, which is expected to reduce the incidence of ablation-related complications. Internally cooled cluster electrodes, for example Cool-tip ones, are straight electrodes without an array of prongs, and the tip is internally cooled by continuous infusion of cold saline. Thus, the temperature of the electrode itself is not extremely high, which is helpful to avoid the instant charring at the tissue around the probe and reduce tissue impedance. The efficient heat deposition creates a larger ablated zone within a shorter period of time. Another advantage of internally cooled electrodes is that they induce a sustaining high temperature in the tumor with limited "heat sink effect" caused by blood flow in the adjacent vessels, which can enhance the ablation effectiveness for the tumor tissue abutting the vessel. Moreover, a specially-designed Cool-tip

electrode is more visible under the guidance of CT or US imaging, which allows the accurate placement of the electrodes in the tumor without injuring the adjacent organs^[31].

Special strategies of ablation for huge hepatic hemangiomas

Larger tumor size is a risk factor for ablation-induced complications. For huge hemangiomas, a few precautions should be taken to lessen the risk of severe complications and enable a successful treatment.

It is unnecessary to achieve a complete ablation of a large tumor using one ablation session if the patient shows the sign of elevating body temperature and hemolysis, considering the severe risk of hemolysis-induced AKI^[36]. A repeat RF ablation session can be rescheduled to obtain the expected treatment effect^[30].

RF ablation combined with TAE could be an option to achieve a synergistic treatment effect for huge hepatic hemangiomas because the blockade of tumor blood supply by TAE can decrease the lesion size to some extent, facilitating the subsequent RF ablation and minimizing the risk of ablation-related complications. Additionally, the hyper-attenuation of iodized oil deposited in the tumor on CT images can facilitate the targeting placement of the RF electrodes in the tumor and thus increase the success rate of complete ablation^[34].

Laparoscopic resection of hemangioma boosted by intratumoral coagulation by RF ablation is a safe, effective option for treating huge hepatic subcapsular hemangiomas with low loss of blood and minimal complications. This technique lies in the advantage that a completely coagulated zone created by sequential RF ablation along the dissection margin warrants the successful removal of the tumor tissue without occluding the hepatic vessels before the tumor dissection. Compared with treating the tumor using RF ablation alone, this technique involves the ablation of the tumor tissue at the resection margin rather than the total hepatic hemangioma, thus shortens the ablation time and avoids the incidence of severe ablation-related complications^[37].

COMPLICATIONS

Hemorrhage of hepatic hemangioma

Bleeding at the electrode entry site: Due to the hypervascular nature of hepatic hemangioma and intratumoral high blood pressure, there is high risk of bleeding from the puncture site of the tumor. To prevent bleeding, the electrode needs to be advanced *via* a transhepatic approach to target the tumor and a needle tract ablation needs to be performed while withdrawing the electrode. When the RF electrode

placement is performed *via* laparotomy or laparoscopic approach, RF ablation should be launched from the exterior margin of the tumor from the beginning of a lower RF power^[31-34].

Rupture of hepatic hemangioma: Abrupt rupture of hepatic hemangioma could result in massive hemorrhage. For hemangiomas located in the surface of the liver, an improper advancement of the RF electrode directly through the tumor will lose the protection of liver parenchyma. In this context, the RF electrode puncture could induce massive bleeding from the electrode puncture site. On the other hand, when an extra-high RF output power is applied at the beginning of RF ablation, a rapid increase of intratumoral temperature and pressure will induce the burst force in the tumor, which will cause an abrupt rupture of the tumor and life-threatening bleeding. Under the direct view of laparoscopy, hemostasis procedure can be applied to the bleeding site such as applying ablation to stop bleeding. In case the bleeding is not controlled by these measures, a conversion to open surgery is advocated to achieve hemostasis.

Puncture injury to adjacent organs

The accidental injuries to the adjacent organs including the gallbladder, gastrointestinal organs, kidney, diaphragm, lungs, and heart need to avoid. While using multipolar expandable electrodes, the deployment of each prong of the electrodes need to be verified carefully^[28,40]. The high visibility of Cool-tip electrodes on CT or US images facilitates the insertion of the electrodes in the tumor without causing accidental injury to adjacent organs^[31].

Thermal injury to the pleura and diaphragm

For hepatic hemangiomas situated in the subdiaphragm hepatic dome area, thermal injuries to the diaphragm frequently occur during RF ablation *via* the percutaneous approach^[32]. The thermal injury to the diaphragm may manifest as the shoulder pain because the diaphragm and the shoulder skin are innervated by the same phrenic nerves arising from nerve roots C3, C4, and C5^[32,41]. Diaphragmatic perforation and herniation were reported as major complications of RF ablation for hepatic tumors abutting the diaphragm in nine cases^[41]. RF ablation injuries more frequently occur in cases with hepatic hemangiomas than hepatic cancers due to the high thermal energy and duration needed for large-sized hemangiomas. RF ablation *via* a laparoscopic approach can minimize the risk of diaphragm injury because the pneumoperitoneum can elevate the diaphragm to increase the operation space. Therefore, laparoscopic RF ablation therapy should be used as the first-line treatment for hepatic

hemangiomas abutting the diaphragm^[32].

Thermal injury to the lung

A patient with two huge hemangiomas in the right lobe (16.0 cm and 11.0 cm), treated with percutaneous RF ablation, developed ARDS immediately after an ablative time of total 250 min^[28]. The major complication was resolved by conservative treatment^[28]. The pathogenesis of ARDS needs to be investigated, and it is speculated that RF ablation of large quantity of tumor tissues induces significant systemic inflammatory responses^[42-45]. Pre-ablation TAE as an adjuvant therapy or multiple ablation sessions is recommended to prevent the risk of ARDS^[31,34].

Hemolysis

Hemolysis and anemia: RF ablation poses a risk of predisposing huge hypervascular hepatic hemangiomas to the severe complication of hemolysis. Hemolysis can lead to various degrees of hemoglobinuria, hemolytic jaundice, anemia, or even AKI^[28-31,36].

AKI: AKI caused by ablation-induced hemolysis in patients with huge hepatic hemangiomas has been reported^[36]. Hemoglobin is released upon erythrocyte destruction and is filtered by the glomerulus into the urinary space. In the urinary space, hemoglobin is degraded and releases heme pigments which can cause tubular injury. Furthermore, volume depletion enhances both vasoconstriction and the formation of obstructing casts, and also is of critical importance for the development of heme-induced AKI^[36].

Patients with huge hepatic hemangiomas should be sufficiently hydrated before RF ablation and during the procedure. When any signs or symptoms indicating hemolysis emerge in the course of RF ablation, such as rising body temperature and hemoglobinuria, the RF procedure should be terminated and a repeat RF ablation treatment may need to be rescheduled based on a comprehensive evaluation of the tumor^[31].

Other complications

Except for relatively severe RF ablation-related complications, some minor complications may take place, such as liver damage, fever, and skin burn injury at the site where the grounding pad is attached. The ablation-induced self-limiting liver injury can resolve within a short period of time without the need of any medication. The necrotic tissue of tumors can cause unspecific inflammatory reaction and mild hyperthermia. In case that the body temperature is higher than 39 °C, physical cooling can be used to alleviate the discomfort of hyperthermia. To prevent the burn injury to the skin in patients receiving long time RF ablation, multiple grounding pads can be

Table 2 Ablation-related complications and preventive measures

Complication	Preventive measures
Bleeding at the electrode entry site	The electrode needs to be advanced <i>via</i> a transhepatic approach to target the tumor and a needle tract ablation needs to be performed while withdrawing the electrode. Radiofrequency (RF) ablation should be launched from the exterior margin of the tumor from the beginning of a lower RF power.
Rupture of hepatic hemangioma	Under the direct view of laparoscopy, hemostasis procedure can be applied to the bleeding site such as applying ablation to stop the bleeding. If it fails, a conversion to open surgery is advocated to achieve the hemostasis.
Puncture injury to adjacent organs	The high visibility of Cool-tip electrodes on computed tomography or ultrasonography images facilitates the insertion of the electrodes in the tumor without causing accidental injury to adjacent organs.
Thermal injury to the pleura and diaphragm	Laparoscopic RF ablation should be used as the first-line treatment for hepatic hemangiomas abutting the diaphragm.
Thermal injury to the lung	Pre-ablation transcatheter arterial embolization as an adjuvant therapy or multiple ablation sessions is recommended to prevent the risk of acute respiratory distress syndrome.
Hemolysis	The patients should be sufficiently hydrated before RF ablation and during the procedure. When any signs or symptoms indicating the hemolysis emerge in the course of ablation, the RF procedure should be terminated and a repeat RF ablation treatment may need to be rescheduled based on a comprehensive evaluation of the tumor.
Liver damage	The ablation-induced liver injury can resolve spontaneously without the need of any medication.
Fever	Physical cooling can be used to alleviate the discomfort of hyperthermia.
Skin burn injury	Multiple grounding pads can be applied or ice pad can be used to cool the skin with the contact of grounding pad.

applied or ice pad can be used to cool the skin with the contact of grounding pad^[31-33]. The ablation-related complications and preventive measures are listed in Table 2.

POST-TREATMENT EVALUATION

Contrast-enhanced CT or MRI can be used to evaluate the therapeutic effect of RF ablation for tumors one month after the treatment. On contrast-enhanced CT or MRI, complete ablation is defined as no nodular or irregular enhancement adjacent to the ablation zone and incomplete ablation is defined as irregular peripheral-enhanced foci in the ablation zone. In cases of complete ablation, subsequent CT or MRI examinations are repeated at a 6-mo interval^[31-33]. Repeated RF ablation procedures are not needed unless the residual tumor is growing significantly or posing a risk of spontaneous rupture.

CONCLUSION

RF ablation therapy is a safe, feasible, and effective procedure for hepatic hemangiomas, even for huge hepatic hemangiomas. RF ablation has the following advantages in the treatment of hepatic hemangiomas: minimal invasiveness, definite efficacy, high safety, fast recovery, relatively simple operation, and wide applicability.

REFERENCES

- 1 Yeh WC, Yang PM, Huang GT, Sheu JC, Chen DS. Long-term follow-up of hepatic hemangiomas by ultrasonography: with emphasis on the growth rate of the tumor. *Hepatogastroenterology* 2007; **54**: 475-479 [PMID: 17523302]
- 2 Schnellrdorfer T, Ware AL, Smoot R, Schleck CD, Harmsen WS, Nagorney DM. Management of giant hemangioma of the liver: resection versus observation. *J Am Coll Surg* 2010; **211**: 724-730 [PMID: 20980175 DOI: 10.1016/j.jamcollsurg.2010.08.006]
- 3 Hasan HY, Hinshaw JL, Borman EJ, Gegios A, Levenson G, Winslow ER. Assessing normal growth of hepatic hemangiomas during long-term follow-up. *JAMA Surg* 2014; **149**: 1266-1271 [PMID: 25321079 DOI: 10.1001/jamasurg.2014.477]
- 4 Bajenaru N, Balaban V, Săvulescu F, Campeanu I, Patrascu T. Hepatic hemangioma -review-. *J Med Life* 2015; **8** Spec Issue: 4-11 [PMID: 26361504]
- 5 Hoekstra LT, Bieze M, Erdogan D, Roelofs JJ, Beuers UH, van Gulik TM. Management of giant liver hemangiomas: an update. *Expert Rev Gastroenterol Hepatol* 2013; **7**: 263-268 [PMID: 23445235 DOI: 10.1586/egh.13.10]
- 6 Mocchegiani F, Vincenzi P, Coletta M, Agostini A, Marzioni M, Baroni GS, Giovagnoni A, Guerrieri M, Marmorale C, Risaliti A, Vivarelli M. Prevalence and clinical outcome of hepatic haemangioma with specific reference to the risk of rupture: A large retrospective cross-sectional study. *Dig Liver Dis* 2016; **48**: 309-314 [PMID: 26514738 DOI: 10.1016/j.dld.2015.09.016]
- 7 Toro A, Mahfouz AE, Ardiri A, Malaguarnera M, Malaguarnera G, Loria F, Bertino G, Di Carlo I. What is changing in indications and treatment of hepatic hemangiomas. A review. *Ann Hepatol* 2014; **13**: 327-339 [PMID: 24927603]
- 8 Miura JT, Amini A, Schmockler R, Nichols S, Sukato D, Winslow ER, Spolverato G, Ejaz A, Squires MH, Kooby DA, Maithel SK, Li A, Wu MC, Sarmiento JM, Bloomston M, Christians KK, Johnston FM, Tsai S, Turaga KK, Tsung A, Pawlik TM, Gamblin TC. Surgical management of hepatic hemangiomas: a multi-institutional experience. *HPB (Oxford)* 2014; **16**: 924-928 [PMID: 24946109 DOI: 10.1111/hpb.12291]
- 9 Li M, Zhang C, Zhang T, Wang L, Ding Y, Niu Z, He S, Yang Z. Outcome using selective hemihepatic vascular occlusion and Pringle maneuver for hepatic resection of liver cavernous hemangioma. *World J Surg Oncol* 2015; **13**: 267 [PMID: 26338222 DOI: 10.1186/s12957-015-0680-9]
- 10 Zhang W, Huang ZY, Ke CS, Wu C, Zhang ZW, Zhang BX, Chen YF, Zhang WG, Zhu P, Chen XP. Surgical Treatment of Giant Liver Hemangioma Larger Than 10cm: A Single Center's Experience With 86 Patients. *Medicine (Baltimore)* 2015; **94**: e1420 [PMID: 26313792 DOI: 10.1097/MD.0000000000001420]

- 11 **Giavroglou C**, Economou H, Ioannidis I. Arterial embolization of giant hepatic hemangiomas. *Cardiovasc Intervent Radiol* 2003; **26**: 92-96 [PMID: 12522645 DOI: 10.1007/s00270-002-2648-8]
- 12 **Huang XQ**, Huang ZQ, Duan WD, Zhou NX, Feng YQ. Severe biliary complications after hepatic artery embolization. *World J Gastroenterol* 2002; **8**: 119-123 [PMID: 11833085 DOI: 10.3748/wjg.v8.i1.119]
- 13 **Firouznia K**, Ghanaati H, Alavian SM, Nassiri Toosi M, Ebrahimi Daryani N, Jalali AH, Shakiba M, Hosseinverdi S. Management of liver hemangioma using trans-catheter arterial embolization. *Hepat Mon* 2014; **14**: e25788 [PMID: 25737731 DOI: 10.5812/hepatmon.25788]
- 14 **Bailey J**, Di Carlo S, Blackwell J, Gomez D. Same day arterial embolisation followed by hepatic resection for treatment of giant haemangioma. *BMJ Case Rep* 2016; **2016**: [PMID: 26917792 DOI: 10.1136/bcr-2015-213259]
- 15 **Park WC**, Rhillips R. The role of radiation therapy in the management of hemangiomas of the liver. *JAMA* 1970; **212**: 1496-1498 [PMID: 5467542]
- 16 **Gaspar L**, Mascarenhas F, da Costa MS, Dias JS, Afonso JG, Silvestre ME. Radiation therapy in the unresectable cavernous hemangioma of the liver. *Radiother Oncol* 1993; **29**: 45-50 [PMID: 8295987]
- 17 **Cui Y**, Zhou LY, Dong MK, Wang P, Ji M, Li XO, Chen CW, Liu ZP, Xu YJ, Zhang HW. Ultrasonography guided percutaneous radiofrequency ablation for hepatic cavernous hemangioma. *World J Gastroenterol* 2003; **9**: 2132-2134 [PMID: 12970923 DOI: 10.3748/wjg.v9.i9.2132]
- 18 **Zagoria RJ**, Roth TJ, Levine EA, Kavanagh PV. Radiofrequency ablation of a symptomatic hepatic cavernous hemangioma. *AJR Am J Roentgenol* 2004; **182**: 210-212 [PMID: 14684541 DOI: 10.2214/ajr.182.1.1820210]
- 19 **Fan RF**, Chai FL, He GX, Li RZ, Wan WX, Bai MD, Zhu WK, Cao ML, Li HM, Yan SZ. [Clinical evaluation of radiofrequency ablation therapy in patients with hepatic cavernous hemangiomas]. *Zhonghua Yi Xue Za Zhi* 2005; **85**: 1608-1612 [PMID: 16185527]
- 20 **Fan RF**, Chai FL, He GX, Wei LX, Li RZ, Wan WX, Bai MD, Zhu WK, Cao ML, Li HM, Yan SZ. Laparoscopic radiofrequency ablation of hepatic cavernous hemangioma. A preliminary experience with 27 patients. *Surg Endosc* 2006; **20**: 281-285 [PMID: 16362478 DOI: 10.1007/s00464-005-0184-8]
- 21 **Tak WY**, Park SY, Jeon SW, Cho CM, Kweon YO, Kim SK, Choi YH, Chung JM. Ultrasonography-guided percutaneous radiofrequency ablation for treatment of a huge symptomatic hepatic cavernous hemangioma. *J Clin Gastroenterol* 2006; **40**: 167-170 [PMID: 16394880]
- 22 **Fan RF**, Chai FL, He GX, Wan WX, Bai MD, Cao ML, Li HM, Yan SZ. [Radiofrequency ablation therapy combined with suture and ligation surgery for patients with giant cavernous hemangiomas of the liver]. *Zhonghua Yi Xue Za Zhi* 2006; **86**: 2134-2137 [PMID: 17064621]
- 23 **Hinshaw JL**, Laeske PJ, Weber SM, Lee FT Jr. Multiple-electrode radiofrequency ablation of symptomatic hepatic cavernous hemangioma. *AJR Am J Roentgenol* 2007; **189**: W146-W149 [PMID: 17715082 DOI: 10.2214/AJR.05.0750]
- 24 **Ha JF**, Sudhakar R, Chandraratna H. Combination laparoscopic radiofrequency ablation and partial excision of hepatic hemangioma. *Ochsner J* 2008; **8**: 205-207 [PMID: 21603503]
- 25 **Park SY**, Tak WY, Jung MK, Jeon SW, Cho CM, Kweon YO, Kim KC. Symptomatic-enlarging hepatic hemangiomas are effectively treated by percutaneous ultrasonography-guided radiofrequency ablation. *J Hepatol* 2011; **54**: 559-565 [PMID: 21115209 DOI: 10.1016/j.jhep.2010.07.024]
- 26 **Sharpe EE 3rd**, Dodd GD 3rd. Percutaneous radiofrequency ablation of symptomatic giant hepatic cavernous hemangiomas: report of two cases and review of literature. *J Vasc Interv Radiol* 2012; **23**: 971-975 [PMID: 22720896 DOI: 10.1016/j.jvir.2012.03.010]
- 27 **Zou H**, Yan J, Wu YX, Ou X, Li XW, Xia F, Ma KS, Bie P. [The new technology of enhanced radiofrequency ablation is safe and effective for treating giant hepatic hemangioma]. *Zhonghua Gan Zang Bing Za Zhi* 2012; **20**: 261-265 [PMID: 22964145 DOI: 10.3760/cma.j.issn.1007-3418.2012.04.007]
- 28 **Gao J**, Ke S, Ding XM, Zhou YM, Qian XJ, Sun WB. Radiofrequency ablation for large hepatic hemangiomas: initial experience and lessons. *Surgery* 2013; **153**: 78-85 [PMID: 22853860 DOI: 10.1016/j.surg.2012.06.004]
- 29 **Zhang X**, Yang J, Yan L. Education and Imaging. Hepatobiliary and pancreatic: radiofrequency ablation for caudate lobe hemangioma. *J Gastroenterol Hepatol* 2013; **28**: 765 [PMID: 23614345 DOI: 10.1111/jgh.12171]
- 30 **van Tilborg AA**, Nielsen K, Scheffer HJ, van den Tol P, van Waesberghe JH, Sietses C, Meijerink MR. Bipolar radiofrequency ablation for symptomatic giant (>10 cm) hepatic cavernous haemangiomas: initial clinical experience. *Clin Radiol* 2013; **68**: e9-e14 [PMID: 23146554 DOI: 10.1016/j.crad.2012.08.029]
- 31 **Gao J**, Ding X, Ke S, Xin Z, Ning C, Sha Q, Sun W. Radiofrequency ablation in the treatment of large hepatic hemangiomas: a comparison of multitined and internally cooled electrodes. *J Clin Gastroenterol* 2014; **48**: 540-547 [PMID: 24926624 DOI: 10.1097/MCG.0b013e31829ef037]
- 32 **Gao J**, Kong J, Ding XM, Ke S, Niu HG, Xin ZH, Ning CM, Guo SG, Li XL, Zhang L, Dong YH, Sun WB. Laparoscopic vs computerized tomography-guided radiofrequency ablation for large hepatic hemangiomas abutting the diaphragm. *World J Gastroenterol* 2015; **21**: 5941-5949 [PMID: 26019459 DOI: 10.3748/wjg.v21.i19.5941]
- 33 **Gao J**, Ji JS, Ding XM, Ke S, Xin ZH, Ning CM, Guo SG, Li XL, Dong YH, Sun WB. Laparoscopic Radiofrequency Ablation for Large Subcapsular Hepatic Hemangiomas: Technical and Clinical Outcomes. *PLoS One* 2016; **11**: e0149755 [PMID: 26901132 DOI: 10.1371/journal.pone.0149755]
- 34 **Ji J**, Gao J, Zhao L, Tu J, Song J, Sun W. Computed Tomography-Guided Radiofrequency Ablation Following Transcatheter Arterial Embolization in Treatment of Large Hepatic Hemangiomas. *Medicine (Baltimore)* 2016; **95**: e3402 [PMID: 27082617 DOI: 10.1097/MD.0000000000003402]
- 35 **Zhang X**, Yan L, Li B, Wen T, Wang W, Xu M, Wei Y, Yang J. Comparison of laparoscopic radiofrequency ablation versus open resection in the treatment of symptomatic-enlarging hepatic hemangiomas: a prospective study. *Surg Endosc* 2016; **30**: 756-763 [PMID: 26123327 DOI: 10.1007/s00464-015-4274-y]
- 36 **van Tilborg AAJM**, Dresselaars HF, Scheffer HJ, Nielsen K, Sietses C, van den Tol PM, Meijerink MR. RF Ablation of Giant Hemangiomas Inducing Acute Renal Failure: A Report of Two Cases. *Cardiovasc Intervent Radiol* 2016; **39**: 1644-1648 [PMID: 27387187 DOI: 10.1007/s00270-016-1415-1]
- 37 **Wang S**, Gao J, Yang M, Ke S, Ding X, Kong J, Xu L, Sun W. Intratumoral coagulation by radiofrequency ablation facilitated the laparoscopic resection of giant hepatic hemangioma: a surgical technique report of two cases. *Oncotarget* 2017; **8**: 52006-52011 [PMID: 28881707 DOI: 10.18632/oncotarget.18994]
- 38 **Vagefi PA**, Klein I, Gelb B, Hameed B, Moff SL, Simko JP, Fix OK, Eilers H, Feiner JR, Ascher NL, Freise CE, Bass NM. Emergent orthotopic liver transplantation for hemorrhage from a giant cavernous hepatic hemangioma: case report and review. *J Gastrointest Surg* 2011; **15**: 209-214 [PMID: 20549381 DOI: 10.1007/s11605-010-1248-1]
- 39 **Dindo D**, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; **240**: 205-213 [PMID: 15273542]
- 40 **Gao J**, Sun WB, Tong ZC, Ding XM, Ke S. Successful treatment of acute hemorrhagic cardiac temponade in a patient with hepatocellular carcinoma during percutaneous radiofrequency ablation. *Chin Med J (Engl)* 2010; **123**: 1470-1472 [PMID: 20819611]

- 41 **Zhou M**, He H, Cai H, Chen H, Hu Y, Shu Z, Deng Y. Diaphragmatic perforation with colonic herniation due to hepatic radiofrequency ablation: A case report and review of the literature. *Oncol Lett* 2013; **6**: 1719-1722 [PMID: 24260068 DOI: 10.3892/ol.2013.1625]
- 42 **Ng KK**, Lam CM, Poon RT, Shek TW, Ho DW, Fan ST. Safety limit of large-volume hepatic radiofrequency ablation in a rat model. *Arch Surg* 2006; **141**: 252-258 [PMID: 16549690 DOI: 10.1001/archsurg.141.3.252]
- 43 **Ziemlewicz TJ**, Wells SA, Lubner MA, Musat AI, Hinshaw JL, Cohn AR, Lee FT Jr. Microwave ablation of giant hepatic cavernous hemangiomas. *Cardiovasc Intervent Radiol* 2014; **37**: 1299-1305 [PMID: 25023180 DOI: 10.1007/s00270-014-0934-x]
- 44 **Liu L**, Li N. Feasibility and Advantages of Large Liver Hemangioma Treated with Laparoscopic Microwave Ablation. *Hepatogastroenterology* 2014; **61**: 1068-1073 [PMID: 26158167]
- 45 **Tang XY**, Wang Z, Wang T, Cui D, Zhai B. Efficacy, safety and feasibility of ultrasound-guided percutaneous microwave ablation for large hepatic hemangioma. *J Dig Dis* 2015; **16**: 525-530 [PMID: 24945806 DOI: 10.1111/1751-2980.12169]

P- Reviewer: Atta H, Habib NA, Moris D **S- Editor:** Ma YJ

L- Editor: Wang TQ **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045